<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928524</url>
  </required_header>
  <id_info>
    <org_study_id>KFE 12.17</org_study_id>
    <nct_id>NCT01928524</nct_id>
  </id_info>
  <brief_title>Chemotherapy for Patients With Cancer of the Stomach</brief_title>
  <acronym>DOS</acronym>
  <official_title>Phase I Trial With Docetaxel, Oxaliplatin and S1 as First-line Treatment for Patients With Non-resectable Adenocarcinoma of the Esophagus or Gastric</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per Pfeiffer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine maximal tolerable dose (MTD) of the combination of&#xD;
      docetaxel, oxaliplatin and S1 (DOS) to patients with gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this dose-finding study is to determine the maximum tolerated doses of&#xD;
      docetaxel, oxaliplatin and S1 given every second (DOS2w) or third (DOS3w) week as first-line&#xD;
      treatment in patients with advanced gastro-esophageal cancer. Secondary end points are to&#xD;
      evaluate toxicities according to NCI-CTCAE v. 4, response rate, progression-free survival and&#xD;
      overall survival&#xD;
&#xD;
      Primary Outcome Measure:&#xD;
&#xD;
      To determine maximum tolerated dose (MTD) for the the combination regimes (DOS2w) and&#xD;
      (DOS3w).&#xD;
&#xD;
      The investigators have planned to examine 4 dose levels of (DOS2w) and 3 dose levels of&#xD;
      (DOS3w).&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      This dose-finding study is planned to include a total of 24 patients with advanced&#xD;
      gastro-esophageal cancer, adenocarcinoma.&#xD;
&#xD;
      12 patients will be included in (DOS2w) at four at progressively higher dose levels.&#xD;
&#xD;
      Chemotherapy will be repeated day 1 every second week to a maximum of nine courses.&#xD;
&#xD;
      12 patients will be included in (DOS3w) at three progressively higher dose levels.&#xD;
&#xD;
      Chemotherapy will be repeated day 1 every third week to a maximum of six courses.&#xD;
&#xD;
      In both (DOS2w) and (DOS3w) dose-limiting toxicity (DLT) will be evaluated after the first&#xD;
      course. In case of DLT among one of the three patients during the first course of treatment&#xD;
      additional three patients will be added at the respective dose level. Dose escalation is&#xD;
      continues if 0/3 or 1/6 patients experience DLT.&#xD;
&#xD;
      Patients will be evaluated with a ct-scan at baseline and after every three or four cycles to&#xD;
      exclude progression and evaluate response. Response is assessed by the investigator according&#xD;
      to RECIST version 1.1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 17, 2015</completion_date>
  <primary_completion_date type="Actual">June 5, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Two parallel phase 1/2a studies with 3+3 design with either DOS given every second week or every third week in Caucasian patients (Table 1). Patients were included into DOS2w and DOS3w in sequence.&#xD;
In the DOS2w group: Patients received escalating doses of Docetaxel (30-50 mg/m2 on Day 1), fixed doses of O (70 mg/ m2 on Day 1) and S-1 (30-35 mg/m2/day twice daily orally on Days 1-7) every two weeks. In the DOS3w group: Patients received escalating doses of docetaxel (40-60 mg/m2 on Day 1), fixed doses of O (100 mg/ m2 on Day 1) and S-1 (25 mg/m2/day twice daily orally on Days 1-14) every three weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Overall Survival</measure>
    <time_frame>Up to 2 years after first administration of DOS</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>First-line Treatment for Patients With Non-resectable Gastric Cancer or Cancer of the Esophagus or</condition>
  <arm_group>
    <arm_group_label>DOS2W Dose level 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DOS2W Dose level 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DOS2W Dose level 3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DOS2W Dose level 4A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DOS3W Dose level 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DOS3W Dose level 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DOS3W Dose level 3B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOS2w Dose level 1A</intervention_name>
    <description>Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (60 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.</description>
    <arm_group_label>DOS2W Dose level 1A</arm_group_label>
    <other_name>DOS2w 1A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOS2w Dose level 2A</intervention_name>
    <description>Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.</description>
    <arm_group_label>DOS2W Dose level 2A</arm_group_label>
    <other_name>DOS2w 2A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOS2w Dose level 3A</intervention_name>
    <description>Docetaxel (40 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.</description>
    <arm_group_label>DOS2W Dose level 3A</arm_group_label>
    <other_name>DOS2w 3A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOS2w Dose level 4A</intervention_name>
    <description>Docetaxel (50 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.</description>
    <arm_group_label>DOS2W Dose level 4A</arm_group_label>
    <other_name>DOS2w 4A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOS3w Dose level 1B</intervention_name>
    <description>Docetaxel (40 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.</description>
    <arm_group_label>DOS3W Dose level 1B</arm_group_label>
    <other_name>DOS3w 1B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOS3w Dose level 2B</intervention_name>
    <description>Docetaxel (50 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.</description>
    <arm_group_label>DOS3W Dose level 2B</arm_group_label>
    <other_name>DOS3w 2B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOS3w Dose level 3B</intervention_name>
    <description>Docetaxel (60 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.</description>
    <arm_group_label>DOS3W Dose level 3B</arm_group_label>
    <other_name>DOS3w 3B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological proven adenocarcinoma of the esophagus or the ventricle (ECV), and which&#xD;
             cannot be treated curatively.&#xD;
&#xD;
          2. Age ≥ 18 years.&#xD;
&#xD;
          3. WHO performance status 0-1.&#xD;
&#xD;
          4. Neutrophils ≥ 1,5 x 109/L and platelets ≥ 100 x 109/L.&#xD;
&#xD;
          5. Bilirubin ≤ 1,5 x UNL (Upper Normal Limit) and ASAT and/or ALAT ≤ 3 x UNL.&#xD;
&#xD;
          6. Creatinine-clearance ≥ 60 ml/min.&#xD;
&#xD;
          7. Planned first day of treatment within 8 days after inclusion in the study.&#xD;
&#xD;
          8. Signed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No previous treatment with chemotherapy, except for (neo)-adjuvant chemotherapy for&#xD;
             adenocarcinoma - treatment should have been completed at least 6 months before&#xD;
             entrance in this study.&#xD;
&#xD;
          2. No sensory neuropathy.&#xD;
&#xD;
          3. No previously treatment with docetaxel, oxaliplatin or S1.&#xD;
&#xD;
          4. No clinical suspicion of brain metastases.&#xD;
&#xD;
          5. No cytotoxic treatment or other experimental treatment within 2 weeks of inclusion in&#xD;
             the study.&#xD;
&#xD;
          6. Other serious disease (i.e. heart disease, AMI within 1 year or ongoing infection).&#xD;
&#xD;
          7. No pregnant women or women who are lactating. Patients who are not using&#xD;
             contraception.&#xD;
&#xD;
          8. No known DPD-deficiency or known allergy to taxanes or platinum.&#xD;
&#xD;
          9. No signs of physical or mental illness that would prevent absorption of oral&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Pfeiffer, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Pfeiffer P, Qvortrup C, Krogh M, Schoennemann K, Vestermark LW, Jensen HA, Bjerregaard JK. S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma: two parallel phase 1/2a studies. Acta Oncol. 2017 Jan;56(1):46-51. doi: 10.1080/0284186X.2016.1257865. Epub 2016 Dec 2.</citation>
    <PMID>27911128</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 21, 2013</study_first_submitted>
  <study_first_submitted_qc>August 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2013</study_first_posted>
  <results_first_submitted>October 29, 2020</results_first_submitted>
  <results_first_submitted_qc>January 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 16, 2021</results_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Per Pfeiffer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer</keyword>
  <keyword>Cancer of the esophagus</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>S1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DOS2w 1A</title>
          <description>3 patients Docetaxel mg/m2 day 1: 30 Oxaliplatin mg/m2 day 1: 70 S-1 mg/m2 days 1-7: 30x2</description>
        </group>
        <group group_id="P2">
          <title>DOS2w 2A</title>
          <description>3 patients Docetaxel mg/m2 day 1: 30 Oxaliplatin mg/m2 day 1: 70 S-1 mg/m2 days 1-7: 35x2</description>
        </group>
        <group group_id="P3">
          <title>DOS 2w 3A</title>
          <description>6 patients Docetaxel mg/m2 day 1: 40 Oxaliplatin mg/m2 day 1: 70 S-1 mg/m2 days 1-7: 35x2</description>
        </group>
        <group group_id="P4">
          <title>DOS2w 4A</title>
          <description>6 patients Docetaxel mg/m2 day 1: 50 Oxaliplatin mg/m2 day 1: 70 S-1 mg/m2 days 1-7: 35x2</description>
        </group>
        <group group_id="P5">
          <title>DOS3w 1B</title>
          <description>3 patients Docetaxel mg/m2 day 1: 40 Oxaliplatin mg/m2 day 1: 100 S-1 mg/m2 days 1-7: 25x2</description>
        </group>
        <group group_id="P6">
          <title>DOS3w 2B</title>
          <description>8 patients Docetaxel mg/m2 day 1: 50 Oxaliplatin mg/m2 day 1: 100 S-1 mg/m2 days 1-7: 25x2</description>
        </group>
        <group group_id="P7">
          <title>DOS3w 3B</title>
          <description>5 patients Docetaxel mg/m2 day 1: 60 Oxaliplatin mg/m2 day 1: 100 S-1 mg/m2 days 1-7: 25x2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DOS2W Dose Level 1A</title>
          <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2nd week.&#xD;
DOS2W: Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (60 mg/m2) will be given every 2nd week. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.</description>
        </group>
        <group group_id="B2">
          <title>DOS3W Dose Level 1B</title>
          <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3rd week.&#xD;
DOS3W: Docetaxel (40 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3rd week. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.</description>
        </group>
        <group group_id="B3">
          <title>DOS2W Dose Level 2A</title>
          <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2nd week.&#xD;
DOS2W: Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2nd week. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.</description>
        </group>
        <group group_id="B4">
          <title>DOS2W Dose Level 3A</title>
          <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2nd week.&#xD;
DOS2W: Docetaxel (40 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2nd week. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.</description>
        </group>
        <group group_id="B5">
          <title>DOS2W Dose Level 4A</title>
          <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2nd week.&#xD;
DOS2W: Docetaxel (50 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2nd week. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.</description>
        </group>
        <group group_id="B6">
          <title>DOS3W Dose Level 2B</title>
          <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3rd week.&#xD;
DOS3W: Docetaxel (50 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3rd week. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.</description>
        </group>
        <group group_id="B7">
          <title>DOS3W Dose Level 3B</title>
          <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3rd week.&#xD;
DOS3W: Docetaxel (60 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3rd week. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="5"/>
            <count group_id="B8" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Overall Survival</title>
        <time_frame>Up to 2 years after first administration of DOS</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DOS2W 1A</title>
            <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2nd week.&#xD;
DOS2W: Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (60 mg/m2) will be given every 2nd week.</description>
          </group>
          <group group_id="O2">
            <title>DOS2W 2A</title>
            <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2nd week.&#xD;
DOS2W: Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2nd week.</description>
          </group>
          <group group_id="O3">
            <title>DOS2W 3A</title>
            <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2nd week.&#xD;
DOS2W: Docetaxel (40 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2nd week.</description>
          </group>
          <group group_id="O4">
            <title>DOS2W 4A</title>
            <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2nd week.&#xD;
DOS2W: Docetaxel (50 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2nd week.</description>
          </group>
          <group group_id="O5">
            <title>DOS3W 1B</title>
            <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3rd week.&#xD;
DOS3W: Docetaxel (40 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3rd week.</description>
          </group>
          <group group_id="O6">
            <title>DOS3W 2B</title>
            <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3rd week.&#xD;
DOS3W: Docetaxel (50 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3rd week.</description>
          </group>
          <group group_id="O7">
            <title>DOS3W 3B</title>
            <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3rd week.&#xD;
DOS3W: Docetaxel (60 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3rd week.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival</title>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O2" value="13.8" lower_limit="7" upper_limit="16"/>
                    <measurement group_id="O3" value="14.6" lower_limit="7" upper_limit="25"/>
                    <measurement group_id="O4" value="15.2" lower_limit="6" upper_limit="26"/>
                    <measurement group_id="O5" value="8.3" lower_limit="5" upper_limit="12"/>
                    <measurement group_id="O6" value="16.4" lower_limit="8" upper_limit="24"/>
                    <measurement group_id="O7" value="7.8" lower_limit="4" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DOS2w Dose Level 1A</title>
          <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2nd week.&#xD;
DOS2w: Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (60 mg/2) will be given every 2nd week.&#xD;
Dose levels are described in the Participant Flow section.</description>
        </group>
        <group group_id="E2">
          <title>DOS2w Dose Level 2A</title>
          <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2nd week.&#xD;
DOS2w: Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2nd week.&#xD;
Dose levels are described in the Participant Flow section.</description>
        </group>
        <group group_id="E3">
          <title>DOS2w Dose Level 3A</title>
          <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2nd week.&#xD;
DOS2w: Docetaxel (40 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2nd week.&#xD;
Dose levels are described in the Participant Flow section.</description>
        </group>
        <group group_id="E4">
          <title>DOS2w Dose Level 4A</title>
          <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2nd week.&#xD;
DOS2w: Docetaxel (50 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2nd week.&#xD;
Dose levels are described in the Participant Flow section.</description>
        </group>
        <group group_id="E5">
          <title>DOS3w Dose Level 1B</title>
          <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3rd week.&#xD;
DOS3w: Docetaxel (40 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 2nd week.&#xD;
Dose levels are described in the Participant Flow section.</description>
        </group>
        <group group_id="E6">
          <title>DOS3w Dose Level 2B</title>
          <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2nd week.&#xD;
DOS3w: Docetaxel (50 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 2nd week.&#xD;
Dose levels are described in the Participant Flow section.</description>
        </group>
        <group group_id="E7">
          <title>DOS3w Dose Level 3B</title>
          <description>Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2nd week.&#xD;
DOS3w: Docetaxel (60 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 2nd week.&#xD;
Dose levels are described in the Participant Flow section.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Diarrhea</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea grade 3-4</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea grade 3-4</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting grade 3-4</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue grade 3-4</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy grade 3-4</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Per Pfeiffer</name_or_title>
      <organization>Odense University Hospital</organization>
      <phone>+45-26283844</phone>
      <email>per.pfeiffer@rsyd.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

